Navigation Links
BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at the Sachs Associates 8th Annual Biotech in Europe Investor Forum in Zurich, Switzerland.

WHEN: Tuesday September 23rd at 11:25am (Local Time)

WHERE: Zurich, Switzerland

About Sachs Associates Biotech in Europe Investor Forum

-------------------------------------------------------

The forum is recognized as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and listed companies with leading investors, analysts, money managers and pharmas.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... Calif. , June 29, 2015   Veracyte, ... company pioneering the field of molecular cytology, today announced ... News Group,s prestigious Top Workplaces list for the second ... Workplace winners based solely on an annual survey of ... and honored that the degree to which Veracyte values ...
(Date:6/29/2015)... -- Elsevier , a world-leading provider ... today announced the highlights of its journal Impact Factor ... Reports® (JCR) published by Thomson Reuters, Elsevier saw 55% ... 2014, ahead of the aggregate across other journals. In ... subject categories, up from 61 in 2013. ...
(Date:6/26/2015)... June 26, 2015   Aratana Therapeutics, ... pet therapeutics company focused on the licensing, ... for companion animals, today announced positive results ... capromorelin (AT-002), the company,s innovative therapeutic for ... small molecule that mimics ghrelin, the naturally ...
(Date:6/26/2015)... MA (PRWEB) , ... June 26, 2015 , ... ... U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded ... to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This ...
Breaking Biology Technology:Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... Sigma Life Science, the innovative biological ... SIAL ), today announced that its SAGE Labs initiative ... (ZFN) technology to generate knock-in rats in which foreign ... genome in a precisely targeted manner.  This breakthrough achievement ...
... QuantaLife, Inc. announced today that it ... of the proceeds will be used to establish commercial ... Digital™ PCR platform, into the life sciences research market ... tests. Paladin Capital Group, together with other existing investors ...
... YORK, Dec. 10, 2010 Ramius V&O Acquisition LLC, ... that it has sent a letter to the Board ... CYPB ) outlining its willingness to acquire all of ... $5.50 per share.  The offer is conditioned upon Cypress ...
Cached Biology Technology:Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 2Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 3Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 4QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... 2013 -- An important new study has revealed the ... influences gene expression profiles of breast cancer. The ... measurements may benefit from pooling of biopsies from a ... Cancer Conference in Brussels, Belgium. These findings represent ...
... Harbor, NY When a pedestrian hears the screech of a ... to move in response. Is the action taking place blocks ... truly primal mechanisms that we depend on every day of our ... sense of hearing -- is yielding its secrets to modern neuroscience. ...
... spill in the Gulf of Mexico, crude oil toxicity ... according to new findings from a research team that ... researchers from Louisiana and South Carolina, the scientists found ... locations show developmental abnormalities, including heart defects, delayed hatching ...
Cached Biology News:Study reveals magnitude of variation in gene expression measurements within breast cancers 2Study reveals magnitude of variation in gene expression measurements within breast cancers 3Scientists discover how brain's auditory center transmits information for decisions, actions 2Scientists discover how brain's auditory center transmits information for decisions, actions 3Health defects found in fish exposed to Deepwater Horizon oil spill 2
... tubes for rodent oral gavage feature soft ... perforation and trauma. Plus they are disposable, ... the risk of cross-contamination. ... 20ga Length: ...
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
Biology Products: